Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

BeiGene has announced that its Tevimbra (tislelizumab) has been approved by the European Commission (EC) as part of a ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic ...

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Results showed tarlatamab demonstrated statistically significant and clinically meaningful improvement in overall survival vs ... for the treatment of small cell lung cancer (SCLC) in patients ...

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...